|
|||||
|
|
A new tumor-specific antigen encoded by <Emphasis Type="Italic">MAGE-C2</Emphasis> and presented to cytolytic T lymphocytes by HLA-B44 |
|
| Authors: | Danièle Godelaine Javier Carrasco Francis Brasseur Bart Neyns Kris Thielemans Thierry Boon Aline Van Pel |
| Institution: | (1) Ludwig Institute for Cancer Research, 74 avenue Hippocrate, UCL 7459, 1200 Brussels, Belgium;(2) Institute of Cellular Pathology, Cellular Genetics Unit, Université Catholique de Louvain, 74 avenue Hippocrate, UCL 7459, 1200 Brussels, Belgium;(3) Department of Medical Oncology, Oncology Center, AZ-VUB, 101 Laarbeeklaan, 1090 Brussels, Belgium;(4) Laboratory of Physiology, Vrije Universiteit Brussel Faculty of Medicine, 103 Laarbeeklaan, 1090 Brussels, Belgium |
| Abstract: | A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination. |
| Keywords: | Antigenic peptide Cancer immunotherapy Cytolytic T lymphocytes MAGE Melanoma |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |